Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP23573 (mTOR inhibitor) in recurrent or persistent endometrial cancer
2004-005094-29Phase 2Completed
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Mar 2006
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ridaforolimus in endometrial cancer (EC), sponsored by ARIAD Pharmaceuticals, Inc. Started Mar 2006; status: completed.
02
Drugs
ridaforolimus
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2004-005094-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005094-29.